Oncology: a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. It includes medical oncology (the use of chemotherapy, hormone therapy, and other drugs to treat cancer), radiation oncology (the use of radiation therapy to treat cancer), and surgical oncology (the use of surgery and other procedures to treat cancer).
One of the main challenges in cancer immunotherapy is the resistance to I-O therapies. Primary resistance can occur before treatment and acquired resistance can occur in patients who respond...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
DATE: June 2, 2020 TIME: 7:00am PT, 10:00am ET In just a few months COVID-19 has risen from a regional crisis to a global threat, and drug makers are now scrambling to develop vaccines aimed...
DATE: May 27, 2020 TIME: 9:00am PT Analysis of antigen- and virus-specific T cells is essential to the understanding of fundamental immunological processes in the contexts of e.g. infectious...
DATE: May 27, 2020 TIME: 8:00am PT, 11:00am ET Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understand...
With over 200 validated antibodies and the option to add custom antibodies, the GeoMx DSP protein portfolio offers options to fit a wide range of spatial profiling application needs. NanoStr...
Background: Despite the immunogenicity and safety profile of dendritic cell (DC) vaccines, the importance of vaccine-induced antigen-specific T cell responses is unclear across clinical tria...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
While many technologies focus on either exploring the spatial context of a handful of targets, or expression patterns of hundreds or thousands of targets in bulk samples or dissociated singl...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
We applied CITE-Seq to measure >150 cell surface immune markers and checkpoint proteins simultaneous to RNA-Sequencing. We resolve the tumour-immune milieu with high precision and reveal...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
Learning Objectives: 1. Participants will become familiar with basic aspects of the user experience with the Genexus system 2. Participants will learn about preliminary studies using a targe...
Operational barriers like complicated workflows and long turnaround times have hindered broad adoption of next-generation sequencing (NGS) in clinical oncology research. The new Ion Torrent...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
One of the main challenges in cancer immunotherapy is the resistance to I-O therapies. Primary resistance can occur before treatment and acquired resistance can occur in patients who respond...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
DATE: June 2, 2020 TIME: 7:00am PT, 10:00am ET In just a few months COVID-19 has risen from a regional crisis to a global threat, and drug makers are now scrambling to develop vaccines aimed...
DATE: May 27, 2020 TIME: 9:00am PT Analysis of antigen- and virus-specific T cells is essential to the understanding of fundamental immunological processes in the contexts of e.g. infectious...
DATE: May 27, 2020 TIME: 8:00am PT, 11:00am ET Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understand...
With over 200 validated antibodies and the option to add custom antibodies, the GeoMx DSP protein portfolio offers options to fit a wide range of spatial profiling application needs. NanoStr...
Background: Despite the immunogenicity and safety profile of dendritic cell (DC) vaccines, the importance of vaccine-induced antigen-specific T cell responses is unclear across clinical tria...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
While many technologies focus on either exploring the spatial context of a handful of targets, or expression patterns of hundreds or thousands of targets in bulk samples or dissociated singl...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
We applied CITE-Seq to measure >150 cell surface immune markers and checkpoint proteins simultaneous to RNA-Sequencing. We resolve the tumour-immune milieu with high precision and reveal...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
Learning Objectives: 1. Participants will become familiar with basic aspects of the user experience with the Genexus system 2. Participants will learn about preliminary studies using a targe...
Operational barriers like complicated workflows and long turnaround times have hindered broad adoption of next-generation sequencing (NGS) in clinical oncology research. The new Ion Torrent...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Follow
